Free Access
Med Sci (Paris)
Volume 22, Number 2, Février 2006
Page(s) 183 - 187
Section M/S revues
Published online 15 February 2006
  1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma : the Eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14 : 7–17. [Google Scholar]
  2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351 : 998–1012. [Google Scholar]
  3. Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst1989; 81 : 1893–904. [Google Scholar]
  4. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313 : 1485–92. [Google Scholar]
  5. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101 : 14639–45. [Google Scholar]
  6. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3 : 666–75. [Google Scholar]
  7. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma : in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99 : 16168–73. [Google Scholar]
  8. Labarriere N, Pandolfino MC, Gervois N, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002; 51 : 532–8. [Google Scholar]
  9. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298 : 850–4. [Google Scholar]
  10. Berd D. M-Vax : an autologous, hapten-modified vaccine for human cancer. Exp Opin Ther 2002; 2 : 335–42. [Google Scholar]
  11. Mitchell MS, Rechtman DJ, Von Eschen KB. A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 1995; 6 (suppl C) : 347. [Google Scholar]
  12. Hsueh E, Gupta R, Qi K, Morton D. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16 : 2913–20. [Google Scholar]
  13. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20 : 4549–54. [Google Scholar]
  14. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells : a critique and a reappraisal. Hum Gene Ther 2000; 11 : 1269–75. [Google Scholar]
  15. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21 : 3343–50. [Google Scholar]
  16. C Castelli, L Rivoltini, F Rini. Heat shock proteins : biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2004 : 53 : 227–233. [Google Scholar]
  17. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes : clinical and immunologic findings. J Clin Oncol 2002; 20 : 4169–80. [Google Scholar]
  18. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines : what have we achieved ? Where are we going ? J Natl Cancer Inst 2002; 94 : 805–18. [Google Scholar]
  19. Daniel E, Speiser A, Mikaël J, et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003; 13 : 461–72. [Google Scholar]
  20. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101 (suppl : 14631-8). [Google Scholar]
  21. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23 : 741–50. [Google Scholar]
  22. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with Iscomatrix adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans. Proc Natl Acad Sci USA 2004; 101 : 10697–702. [Google Scholar]
  23. Thurner B, Haendler I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stages IV melanoma. J Exp Med 1999; 190 : 1669–78. [Google Scholar]
  24. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002; 8 : 1021–32. [Google Scholar]
  25. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2 : 151–61. [Google Scholar]
  26. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7 : 297–303. [Google Scholar]
  27. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61 : 6451–8 [Google Scholar]
  28. Paczesny S, Ueno H, Fay J, et al. Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol 2003; 13 : 439–47. [Google Scholar]
  29. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes : results of the first phase I clinical trial. J Transl Med2005; 3 : 10. [Google Scholar]
  30. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34 : 336–44. [Google Scholar]
  31. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201 : 241–8. [Google Scholar]
  32. Movassagh M, Spatz A, Davoust J, et al. Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 2004; 64 : 2192–8. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.